Research Article
Effectiveness and Safety of PD-1 Inhibitors’ Treatment for Patients with Non-Small-Cell Lung Cancer in China: A Real-World Study
Table 4
Univariate and multivariate analysis of OS in patients treated with immune checkpoint inhibitors.
| Baseline characteristics | Median OS (95% CI) | value (univariate analysis) | HR (95% CI) | value (multivariate analysis) |
| Ages (years) | | 0.944 | | | <65 | 30.10 (17.525–42.675) | | | | ≥65 | 28.60 (20.881–36.319) | | | | Sex | | 0.454 | | | Male | 30.50 (21.816–39.184) | | | | Female | 28.60 (17.757–39.443) | | | | Therapy lines | | 0.643 | | | First-line | 30.10 (22.787–37.413) | | | | Second or more-line | No reached | | | | Smoking history | | 0.067 | | | Current or ex-smoker | 24.60 (14.752–34.448) | | 1.753 (0.922–3.333) | 0.087 | Never-smoker | 30.10 (27.538–32.662) | | Histology | | 0.166 | | | Nonsquamous | 28.60 (22.304–34.896) | | | | Squamous | 30.10 (20.205–39.995) | | | | Pathological staging | | 0.323 | | | III | 30.10 (18.009–42.191) | | | | IV | 28.60 (22.700–34.500) | | | | Presence of treating with antibiotic during immunotherapy | | 0.622 | | | Yes | 28.60 (22.352–34.848) | | | | No | 30.10 (18.092–42.108) | | | | Presence of serious AEs | | 0.014 | | | Yes | 24.50 (17.013–31.987) | | 2.199 (1.130–4.280) | 0.020 | No | 30.10 (27.487–32.713) | | Presence of irAEs | | 0.839 | | | Yes | 24.60 (19.453–29.747) | | | | No | 30.10 (27.698–32.502) | | | |
|
|